Information  X 
Enter a valid email address

Company Name matching 'ObsEva SA'

Date
Time Source
Company
Announcement
08 Sep 2020 6:00 am GNW   ObsEva SA ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020
03 Sep 2020 10:00 pm GNW   ObsEva SA ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million
07 Aug 2020 6:00 am GNW   ObsEva SA ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020
06 Aug 2020 6:00 am GNW   ObsEva SA ObsEva Announces Second Quarter 2020 Financial Results and Business Update
15 Jul 2020 6:00 am GNW   ObsEva SA ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020
06 Jul 2020 6:00 am GNW   ObsEva SA ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
03 Jul 2020 6:00 am GNW   ObsEva SA ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
01 Jul 2020 6:00 am GNW   ObsEva SA ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
29 Jun 2020 6:00 am GNW   ObsEva SA ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids
09 Jun 2020 9:01 pm GNW   ObsEva SA ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020
04 Jun 2020 6:00 am GNW   ObsEva SA ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
29 May 2020 6:00 am GNW   ObsEva SA ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020
08 May 2020 9:30 pm GNW   ObsEva SA ObsEva Annual General Meeting 2020
05 May 2020 9:34 am GNW   ObsEva SA ObsEva Announces First Quarter 2020 Financial Results and Business Update
22 Apr 2020 9:30 pm GNW   ObsEva SA ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
14 Apr 2020 6:00 am GNW   ObsEva SA ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
06 Apr 2020 6:00 am GNW   ObsEva SA ObsEva SA Announces New Interim Chief Financial Officer
27 Mar 2020 6:00 am GNW   ObsEva SA ObsEva SA: New Date Announcement for AGM
23 Mar 2020 6:00 am GNW   ObsEva SA ObsEva Provides Update Related to COVID-19 Pandemic
05 Mar 2020 9:43 am GNW   ObsEva SA ObsEva SA Link to Annual Report 2019
  6:00 am GNW   ObsEva SA ObsEva Announces Year End 2019 Financial Results and Business Update
27 Feb 2020 6:00 am GNW   ObsEva SA ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020
18 Feb 2020 8:48 am GNW   ObsEva SA Correction: ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
15 Jan 2020 6:00 am GNW   ObsEva SA ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
13 Jan 2020 6:00 am GNW   ObsEva SA ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China
07 Jan 2020 6:00 am GNW   ObsEva SA ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020
09 Dec 2019 6:00 am GNW   ObsEva SA ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
06 Dec 2019 9:30 pm GNW   ObsEva SA ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
07 Nov 2019 6:10 am GNW   ObsEva SA ObsEva Announces Third Quarter 2019 Financial Results
  6:00 am GNW   ObsEva SA Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint
06 Nov 2019 9:50 pm GNW   ObsEva SA Correction: ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019
  6:00 am GNW   ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
04 Nov 2019 6:00 am GNW   ObsEva SA ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019
31 Oct 2019 6:00 am GNW   ObsEva SA ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
11 Oct 2019 6:00 am GNW   ObsEva SA ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
09 Oct 2019 6:00 am GNW   ObsEva SA ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
27 Sep 2019 6:00 am GNW   ObsEva SA ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019
11 Sep 2019 9:30 pm GNW   ObsEva SA ObsEva announces new composition of its Executive Committee
03 Sep 2019 6:00 am GNW   ObsEva SA ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
30 Aug 2019 6:00 am GNW   ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
09 Aug 2019 6:00 am GNW   ObsEva SA ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13-14, 2019
07 Aug 2019 6:00 am GNW   ObsEva SA ObsEva Reports Second Quarter 2019 Financial Results
  6:00 am GNW   ObsEva SA ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
05 Aug 2019 6:00 am GNW   ObsEva SA ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019
26 Jul 2019 6:00 am GNW   ObsEva SA ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
18 Jul 2019 6:00 am GNW   ObsEva SA ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
17 Jul 2019 5:00 pm GNW   ObsEva SA ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
12 Jul 2019 6:00 am GNW   ObsEva SA ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
08 Jul 2019 6:00 am GNW   ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
01 Jul 2019 6:00 am GNW   ObsEva SA ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
21 Jun 2019 6:00 am GNW   ObsEva SA ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
19 Jun 2019 6:00 am GNW   ObsEva SA ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
04 Jun 2019 6:00 am GNW   ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
16 May 2019 6:00 am GNW   ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
09 May 2019 6:15 am GNW   ObsEva SA ObsEva Reports First Quarter 2019 Financial Results
  6:00 am GNW   ObsEva SA ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
08 May 2019 9:30 pm GNW   ObsEva SA ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
03 May 2019 6:00 am GNW   ObsEva SA ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
01 May 2019 6:00 am GNW   ObsEva SA ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
29 Apr 2019 6:00 am GNW   ObsEva SA ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t